BLA 761049 · Emd Serono INC
Bavencio
Avelumab · Injection · Programmed Death Ligand-1 Blocker
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 23, 2017
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
269
20 Phase 3, 20 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Avelumab" as an intervention, any sponsor and status, largest first.
EMD Serono Research & Development Institute, Inc.Industry
NCT01772004 · 1,756 participants · Start Jan 31, 2013 · Primary completion Dec 16, 2019
Drug: Avelumab · For: Solid Tumors
Sites: Goodyear, Arizona; Scottsdale, Arizona; Rogers, Arkansas · 74 sites in all
- Avelumab in First-line NSCLC (JAVELIN Lung 100)Pivotal-lookingCompleted
EMD Serono Research & Development Institute, Inc.Industry
NCT02576574 · 1,214 participants · Start Oct 29, 2015 · Primary completion Dec 6, 2021
Drug: Avelumab; Pemetrexed and 7 more · For: First Line Non-Small Cell Lung Cancer
Sites: Huntsville, Alabama; Surprise, Arizona; San Diego, California · 349 sites in all
- Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)Pivotal-lookingTerminated
PfizerPfizer (PFE)
NCT02718417 · 998 participants · Start May 19, 2016 · Primary completion Sep 7, 2018
Drug: carboplatin; paclitaxel and 2 more · For: Ovarian Cancer
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 319 sites in all
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02684006 · 886 participants · Start Mar 23, 2016 · Primary completion Aug 31, 2023
Drug: Avelumab (MSB0010718C); Axitinib (AG-013736) and 1 more · For: Renal Cell Cancer
Sites: Daphne, Alabama; Mobile, Alabama; Beverly Hills, California · 270 sites in all
- Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)Pivotal-lookingCompleted
EMD Serono Research & Development Institute, Inc.Industry
NCT02395172 · 792 participants · Start Mar 24, 2015 · Primary completion Nov 22, 2017
Drug: Avelumab; Docetaxel · For: Carcinoma, Non-Small-Cell Lung
Sites: Tuscaloosa, Alabama; Scottsdale , Phoenix, Arizona; Anaheim, California · 260 sites in all
Institut BergoniéAcademic, hospital or other
NCT03475953 · 747 participants (planned) · Start May 4, 2018 · Primary completion Dec 31, 2024
Drug: Phase 1 : Regorafenib; Phase 1 : Avelumab and 3 more · For: Colorectal Cancer Not MSI-H or MMR-deficient; GIST; Oesophageal or Gastric Carcinoma and 12 more
Sites: Bordeaux, France; Brest, France; Lyon, France · 7 sites in all
- Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)Pivotal-lookingActive, not recruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT02999087 · 707 participants · Start Sep 14, 2017 · Primary completion Dec 2027
Drug: Cetuximab; avelumab and 1 more · For: HNSCC
Sites: Lorient, France
- A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02603432 · 700 participants · Start Apr 25, 2016 · Primary completion Oct 21, 2019
Drug: Avelumab; Following the planned interim analysis for this study: Avelumab · For: Urothelial Cancer
Sites: Aurora, Colorado; New Haven, Connecticut; Boston, Massachusetts · 382 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bavencio (Avelumab)
2024 spending
$2.0M
Beneficiaries
28
170 claims
Per beneficiary
$73,041
$190.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $793,201 |
| 2021 | $1,567,112 |
| 2022 | $1,954,833 |
| 2023 | $2,230,421 |
| 2024 | $2,045,161 |
Part B: Bavencio (Avelumab) · HCPCS J9023
2024 spending
$97.9M
Beneficiaries
1,062
12,217 claims
Per beneficiary
$92,191
2024 ASP limit $93.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $44,264,265 |
| 2021 | $79,095,180 |
| 2022 | $111,862,815 |
| 2023 | $123,396,723 |
| 2024 | $97,907,150 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, et al. · JAMA Oncol 2018 · Meta-Analysis, Systematic Review
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T, Park SH, Voog E, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.
Sonpavde GP, Grivas P, Lin Y, et al. · Future Oncol 2021 · Comparative Study, Meta-Analysis
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.
Papp KA, Puig L, Beecker J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
- Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R, Sousa LG, Feng L, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Emd Serono INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.